Bristol Myers Squibb has agreed to pay Hengrui Pharma up to $15.2 billion, with a $600 million upfront payment and potential milestone payments over time, to advance 13 early-stage oncology, hematology, and immunology programs.
Takeda has announced plans to lay off approximately 4,500 employees worldwide as part of a restructuring aimed at improving efficiency and profitability, according to recent reports.
Daiichi Sankyo has unveiled a new five-year business plan focused on expanding its oncology portfolio, investing heavily in existing and pipeline oncology drugs to strengthen its position as a global leader in cancer therapeutics.## Sources:
BMS inks $15B deal to bag Hengrui assets, tap China's R&D speed
Daiichi Sankyo Unveils New Five-Year Business Plan Focused on ...
BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal
China's Hengrui seals US$15.2 billion deal with US pharmaceutical ...
Bristol Myers Squibb inks $15.2B drug deal with Hengrui - NJBIZ
BMS and Hengrui forge $15.2bn alliance for early-stage drugs